Vanda Pharmaceuticals Inc.  

(Public, NASDAQ:VNDA)   Watch this stock  
Find more results for Vanda Pharmaceuticals Inc
10.09
-0.01 (-0.10%)
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.99 - 10.20
52 week 8.34 - 16.50
Open 10.05
Vol / Avg. 580,664.00/666,417.00
Mkt cap 421.75M
P/E 11.89
Div/yield     -
EPS 0.85
Shares 41.80M
Beta 1.94
Inst. own 113%
Aug 5, 2015
Q2 2015 Vanda Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 18, 2015
Vanda Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 13, 2015
Vanda Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
May 6, 2015
Q1 2015 Vanda Pharmaceuticals Inc Earnings Call - Webcast
May 6, 2015
Q1 2015 Vanda Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -46.14% 40.25%
Operating margin -46.47% 40.00%
EBITD margin - -109.20%
Return on average assets -21.28% 12.81%
Return on average equity -26.17% 19.70%
Employees 64 -
CDP Score - -

Address

Suite 300E, 2200 Pennsylvania Ave NW
WASHINGTON, DC 20037
United States - Map
+1-202-7343400 (Phone)
+1-202-2961450 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. The Company’s product portfolio includes: HETLIOZ (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24); Fanapt (iloperidone), a product for the treatment of schizophrenia, the oral formulation; and VLY-686 (tradipitant), a small molecule neurokinin-1 receptor (NK-1R) antagonist. . Novartis has exclusive commercialization rights to all formulations of Fanapt in the United States and Canada. Novartis is responsible for the further clinical development activities in the United States and Canada.

Officers and directors

H. Thomas Watkins Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Mihael H. Polymeropoulos M.D. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
James Patrick Kelly Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Paolo Baroldi M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 64
Bio & Compensation  - Reuters
Thomas Edward Gibbs Senior Vice President, Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Michael F. Cola Independent Director
Age: 55
Bio & Compensation  - Reuters
Richard W. Dugan Independent Director
Age: 73
Bio & Compensation  - Reuters
Steven K. Galson M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Vincent J. Milano Independent Director
Age: 51
Bio & Compensation  - Reuters